At the 3rd Annual Madhya Pradesh Cancer Conclave (MPCCON), I had the privilege of moderating a session focused on the recent trends in cervical cancer management, with a special emphasis on the results from the INTERLACE trial and the Keynote-A18 and 826 studies.

These trials highlight groundbreaking advancements in cervical cancer treatment, which have the potential to be practice-changing after a decade of limited progress in this field. The INTERLACE trial, in particular, shows great promise and feasibility for implementation in the Indian population, offering a new direction in treatment strategies.

The addition of pembrolizumab to traditional therapies, as shown in the Keynote-A18 study, provides a meaningful benefit, opening up a new era for improved outcomes in cervical cancer therapy.

hashtag#cancer hashtag#MPCCON hashtag#Cervicalcancer